Vaccine-maker Novavax (NVAX) is a $6.5 billion company with only $18 million in trailing sales and no profits whatsoever — but “thanks” to the novel coronavirus, that could soon change. Indeed, in one analyst’s view, as little as a year from now, vaccinating patients against COVID-19 could turn out to be a billion-dollar business for Novavax — or more.But first, the bad news.In a note published Thursday, H.C. Wainwright analyst Vernon Bernardino cites “mathematical models we reviewed online” to argue that contrary to what optimists have been saying, “herd immunity” to infection with coronavirus may not be a viable option …read more
Source:: Yahoo Finance
